Results have been published for a novel drug that appears to help extend the lives of men with advanced prostate cancer, Best Medical Cover has reported.
The oral therapy enzalutamide was found to improve survival by around five months, compared with a placebo.
Scientists tested the drug in men with inoperable prostate cancer whose disease had spread to other parts of the body.
Professor Alan Ashworth, chief executive of the UK's Institute of Cancer Research, said: "What we're seeing now is an unprecedented period of success for prostate cancer research, with four new drugs shown to extend life in major clinical trials in just two years, and several others showing promise."
They found that men who used enzalutamide lived for a median of 18.4 months, compared with just 13.6 months for those taking the placebo.
The findings are published in the New England Journal of Medicine and suggest enzalutamide could be a promising new treatment for the disease.
